Transungual Delivery of Ciclopirox Is Increased 3–4-Fold by Mechanical Fenestration of Human Nail Plate in an In Vitro Model

  1. Damián Córdoba Díaz 3
  2. Marta Elena Losa Iglesias 2
  3. Ricardo Becerro de Bengoa Vallejo 1
  4. Manuel Córdoba Díaz 3
  1. 1 Facultad de Enfermería, Fisioterapia y Podología, Universidad Complutense de Madrid, 28040 Madrid, Spain
  2. 2 Facultad Ciencias de la Salud, Universidad Rey Juan Carlos, 28933 Madrid, Spain
  3. 3 Departamento de Farmacia y Tecnología Farmacéutica, Facultad de Farmacia, Universidad Complutense de Madrid, 28040 Madrid, Spain
Mostrar afiliaciones +
Revista:
Pharmaceutics

ISSN: 1999-4923

Año de publicación: 2019

Volumen: 11

Número: 1

Páginas: 8

Tipo: Artículo

DOI: 10.3390/PHARMACEUTICS11010029 GOOGLE SCHOLAR lock_openAcceso abierto editor

Otras publicaciones en: Pharmaceutics

Objetivos de desarrollo sostenible

Resumen

Onychomycosis is a fungal infection of nails that is widespread and difficult to treat because of the impermeable nature of human nails. Topically applied anti-fungal agents cannot penetrate this structure, and treatment regimens often resort to systemic antifungals with concomitant side effects. One recent clinical study suggested that mechanical fenestration of the nail using an intelligent nail drill might be a possible solution to this problem. In this work, an in vitro model of the transungual delivery of antifungal agents is presented, which utilizes real nail tissue and an inline flow system. This system was deployed to measure transungual delivery of ciclopirox and determined that nail fenestration improved drug delivery by 3–4-fold after 42 days. This study bolsters the argument that nail fenestration should be accepted as a pretreatment for onychomycosis and offers a way of evaluating new drugs or formulations designed to combat this condition.

Referencias bibliográficas

  • 10.3390/pharmaceutics10040276
  • Agache, (2004), pp. 735
  • 10.1002/jps.20901
  • Gupchup, (1999), J. Cosmet. Sci., 50, pp. 363
  • 10.1007/BF00406540
  • 10.1211/0022357991772448
  • 10.2165/00003088-200038020-00001
  • Bristow, (2016), J. Drugs Dermatol., 15, pp. 974
  • 10.1080/03639045.2016.1201098
  • Ema.europa.euhttps://www.ema.europa.eu/documents/scientific-guideline/draft-guideline-investigation-bioequivalence_en.pdf
  • 10.1016/S0168-3659(00)00306-0
  • 10.1016/0378-4347(95)00324-X
  • 10.1016/j.chroma.2011.04.064
  • Patel, (2009), Int. J. Curr. Pharm. Res., 1, pp. 1
  • Borovoy, (1992), Clin. Laser Mon., 10, pp. 123
  • 10.5281/zenodo.1197498